Using real-time PCR analysis, we found clinical lung cancer samples of Osimertinib-resistant tumors had higher levels of ERK2 (MAPK1) mRNA, as compared to Osimertinib-sensitive counterparts (Figure 1C). Here, MAPK1 is linked to lung carcinoma.